PF-08098488 in adults with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 trial evaluates the safety and how PF-08098488 behaves in the body of adults with advanced solid tumors including NSCLC, pancreatic, gastric, GEJ, and esophageal cancers. Participants receive PF-08098488 by IV infusion and are monitored for side effects and signals of helpful activity. The study also looks at how the drug moves through and is processed by the body, to guide future research. Enrollment requires measurable disease, prior therapy, and good performance status.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years of age or older
* Advanced non-small cell lung cancer, pancreatic ductal adenocarcinoma, gastric cancer (including gastroesophageal junction carcinoma), or esophageal cancer.
* Eastern Cooperative Oncology Group (ECOG) Performance status 0-1
* Measurable disease
* Must have received at least 1 prior approved systemic therapy:
* Part 1: progression or relapse following standard treatments and have no other appropriate standard of care option.
* Part 2: maximum of 2 prior lines of systemic therapy in the advanced setting.
* Resolution of acute effects of prior anticancer therapy to baseline or Grade 1
* Consent to submit required pre-treatment tumor tissue as medically feasible

Exclusion Criteria:

* Received prior treatment with an antibody drug conjugate with an auristatin or microtubule inhibitor payload.
* Unacceptable renal, hepatic, hematologic, cardiologic, pulmonary, or abnormalities as defined by the protocol.
* Pre-existing sensory or motor neuropathy.
* Uncontrolled diabetes mellitus.
* Clinically significant and/ or symptomatic eye disease meeting protocol exclusion criteria.
* Pulmonary (lung) disease meeting protocol exclusion criteria.

Where it's running

• START Midwest, LLC
  Grand Rapids, Michigan, United States Recruiting
• Sarah Cannon Research Institute - Pharmacy
  Nashville, Tennessee, United States Recruiting
• SCRI Oncology Partners
  Nashville, Tennessee, United States Recruiting
• START San Antonio, LLC
  San Antonio, Texas, United States Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Sonesitatug vedotin plus capecitabine, with or without rilvegostomig, for CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma

  This trial will test whether adding sonesitatug vedotin to capecitabine, with or without rilvegostomig, helps people with untreated CLDN18.2-positive, HER2-negative advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma.

  Recruiting at 158 sites Phase 3 AstraZeneca · Birmingham, Alabama and 313 other locations · NCT07431281

• PF-08046876 for people with advanced solid tumors

  This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.

  Recruiting at 30 sites Phase 1 Pfizer · Duarte, California and 30 other locations · NCT07090499

• Targeted therapy using Lead-212 for solid tumors

  This study is testing a new targeted radiation treatment for patients with solid tumors that have a specific protein to see if it can effectively treat their cancer while protecting healthy tissue.

  Recruiting at 16 sites Phase 1/2 Perspective Therapeutics · Los Angeles, California and 15 other locations · NCT06710756

• Trimodal prehabilitation program for patients with upper GI and pancreatic cancer

  This study is testing an 8-week program that combines exercise, nutrition help, and mental support for patients with pancreatic or esophageal cancer to see if it can improve their health before surgery.

  Recruiting GERCOR - Multidisciplinary Oncology Cooperative Group · Dijon and 10 other locations · NCT06275737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.